LianBio (NASDAQ:LIAN) Trading 5% Higher

LianBio (NASDAQ:LIAN) traded up 5% on Monday . The company traded as high as $0.32 and last traded at $0.32. 201,363 shares changed hands during mid-day trading, a decline of 81% from the average session volume of 1,037,083 shares. The stock had previously closed at $0.30.

LianBio Stock Performance

The company has a market capitalization of $34.04 million, a price-to-earnings ratio of -0.39 and a beta of 0.23. The stock’s fifty day simple moving average is $0.31 and its two-hundred day simple moving average is $2.21.

Institutional Investors Weigh In On LianBio

A number of institutional investors and hedge funds have recently bought and sold shares of LIAN. Axxcess Wealth Management LLC acquired a new stake in LianBio during the 3rd quarter worth about $25,000. Donald L. Hagan LLC raised its holdings in LianBio by 37.3% during the 4th quarter. Donald L. Hagan LLC now owns 20,600 shares of the company’s stock worth $92,000 after buying an additional 5,600 shares during the period. Finally, Affinity Asset Advisors LLC raised its holdings in LianBio by 462.2% during the 4th quarter. Affinity Asset Advisors LLC now owns 3,779,694 shares of the company’s stock worth $16,895,000 after buying an additional 3,107,337 shares during the period. 74.85% of the stock is owned by institutional investors and hedge funds.

About LianBio

LianBio, a biopharmaceutical company, engages in developing and commercializing medicines for cardiovascular, oncology, opthalmology, and inflammatory diseases in China and other Asian countries. The company develops mavacamten for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy, and heart failure with preserved ejection fraction; TP-03 for the treatment of Demodex blepharitis and meibomian gland disease; NBTXR3 for the treatment of head and neck squamous cell carcinoma, and solid tumor; Infigratinib for the treatment of second-line and first-line cholangiocarcinoma, and gastric cancers; BBP-398 for solid tumors; Omilancor and NX-13 for ulcerative colitis and Crohn's disease; LYR-210 for chronic rhinosinusitis; and Sisunatovir for respiratory syncytical virus.